Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "The Tide-A Study - Avelumab + Intermittent Axitinib in Previously Untreated Patients With mRCC"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Roberto Iacovelli
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Roberto Iacovelli
Login to view comments.
Click here to Login
Genitourinary